期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

^(125)I偶联VEGF反义寡核苷酸对人膀胱癌VEGF的抑制作用研究 被引量：1

Inhibiting Effect of ^(125)I-coupled Vascular Endothelial Growth Factor (VEGF) Antisense Oligonucleotides on Expression of VEGF in Bladder Cancer Cells
下载PDF
导出
摘要 目的观察125I偶联VEGF反义寡核苷酸(125I-ASODN)对膀胱癌细胞VEGF表达的抑制情况。方法采用免疫组化法观察125I-ASODN对膀胱癌细胞VEGF表达的影响,并观察条件培养液对内皮细胞生长的抑制作用。结果免疫组化结果显示对照组VEGF阳性细胞数为平均89.1/100个细胞,125I-Na处理组为90.3/100个细胞,ASODN组为10.3/100个细胞,125I-ASODN组为4.3/100个细胞,125I-ASODN组和ASODN组与对照组及125I-Na组比较,差异有显著性意义(P<0.05);对照组、125I-Na处理组、ASODN组、125I-ASODN组D值分别为0.398±0.031,0.387±0.010,0.298±0.013和0.148±0.011,125I-ASODN组和ASODN组D值与对照组及125I-Na组比较,差异有非常显著性(P<0.01)。结论125I-ASODN能够明显抑制膀胱癌细胞的VEGF表达,可作为临床抗血管生成治疗膀胱癌的一种有效方法。 Objective To study the inhibition effect of VEGF expression in human bladder carcinoma cells by ^125I-coupled antisense oligonucleotides （^125I-ASODN）. Methods VEGF expression in human bladder cancer cells was detected with immunohistochemistry. Endothelial cell growth was assessed after adding conditional medium. Results By immunohistochemistry, the positive cells were 89. 1/100 cells in control group, 90. 3/100 cells in ^125I-Na group, 10. 3 in ASODN group and 4, 3 in ^125I-ASODN group. The D value of each group was 0, 398±0. 031,0, 387 ± 0. 010,0, 298±0. 013 and 0. 148 ± 0. 011. Comparing ^125I-ASODN group and ASODN group with control and ^125I-Na group, difference was significant （P〈0, 05）. Conclusion ^125I-ASODN can effectively suppress VEGF expression of human bladder cancer cells. It has good prospect in canti-angiogenesis of bladder carcinoma.
作者 范海涛 任明 白力刚 王海英 刘禄成
机构地区 吉林大学第二医院泌尿外科 农安县医院泌尿外科
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2005年第10期632-633,647,共3页 Cancer Research on Prevention and Treatment
关键词 反义 寡核苷酸 膀胱癌 血管内皮生长因子 放射性核素 Antisense Oligonucleotides Bladder carcinoma Vascular endothelial growth factor（VEGF） Radionuclide
分类号 R737.14 [医药卫生—肿瘤] R730.23 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Teo NB, Shoker BS, Martin L, et al. Angiogenesis in preinvasive cancers[J]. Anti-cancer Res, 2002, 22(4): 2061-2072.
  • 2Crew JP. Vascular endothelial growth factor: An important angiogenis mediator in bladder cancer?[J]. Eur Urol, 1999, 35(1): 2-8.
  • 3张明,郭航,刘禄成,李然伟,范海涛,朱德淳.VEGF反义寡核苷酸抑制人膀胱癌细胞VEGF表达的作用和效果[J].中国老年学杂志,2004,24(4):329-331. 被引量：5
  • 4Xu D, Kang H, Fisher M, et al. Strategies for inhibition of MDR1 gene expression[J]. Mol Pharmacol, 2004, 66(2): 268-275.
  • 5Jansen B, Zangemeister Wittke U. Antisense therapy for cancer-the time of truth[J]. Lancet Oncol, 2002, 3(11): 672-683.
  • 6杨建辉,张建国,李国华.反义寡核苷酸在恶性肿瘤研究中的现状和展望[J].肿瘤防治研究,2004,31(3):182-184. 被引量：8
  • 7Forster y, Meye A, Krause S, et al. Antisense-mediated VEGF suppression in bladder and breast cancer cells[J]. Cancer Lett, 2004, 212(5): 95-103.
  • 8Kassis AI, Adelstein SJ, Mariani G. Radiolabeled nucleoside analogs in cancer diagnosis and therapy[J]. J Nucl Med, 1996, 40(3): 301-319.
  • 9Panyutin IG, Neumann RD. Sequence specific DNA breaks produced by triple-directed decay of iodine-125[J]. Acta Oncol, 2000, 35(3): 817-823.
  • 10侯英萍,邓敬兰.放射性核素反义治疗防治血管再狭窄的应用前景[J].同位素,2000,13(2):111-114. 被引量：4

二级参考文献30

  • 1兰燕平 崔长琮 等.PTCA术后再狭窄的防治－－在体局部导入反义寡核苷酸的实验研究[J].中国病理生理杂志,1998,14(7):944-945.
  • 2[1]Kanamaru T, Takagi T, Takakura Y, et al. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes[J].J Drug Target,1998,5(4):235-237.
  • 3[2]Yuen A, Advani R, Fisher G,et al.A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer[J]. Am Soc Clin Oncol, 2000,19(6): 459-461.
  • 4[3]Webb A, Cunningham D, Cotter F,et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma[J].Lancet, 1997,349(9059):1137-1141.
  • 5[4]Jansen B, Wacheck V, Heere-Ress E,et al.Chemosensitisation of malignant melanoma by BCL2 antisense therapy[J]. Lancet, 2000,356(9243):1728-1733.
  • 6[5]Chi KN, Gleave ME, Klasa R,et al.A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer[J]. Clin Cancer Res,2001, 7(12):3920-3927.
  • 7[6]C.M.Rudin, G.A.Otterson, A. M. Mauer, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer[J]. Annals of Oncology, 2002,13(4):539-545.
  • 8[7]Banerjee D. Genasense (Genta Inc).Curr Opin Investig Drugs[J]. 2001, 2(4):574-580.
  • 9[8]Fennell DA, Corbo MV, Dean NM,et al.In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model[J].Br J Haematol, 2001,112(3):706-713.
  • 10[9]Monia BP. First and second-generation antisense inhibits targers to human c-raf kinase:in vitro and in vivo studies[J]. Anticancer Drugs Des,1997,12(5):327-339.

共引文献14

同被引文献11

  • 1范海涛,任明,白利群,张兵,朱德淳,刘禄成.端粒酶抑制剂与丝裂霉素联合应用对膀胱癌的作用研究[J].肿瘤防治研究,2005,32(9):574-576. 被引量：1
  • 2Toim M,Matsumoto T,Bando H.Vascular endothelial growth factor:its prognostic,predictive,and therapeutic implication[J].Lancet Oncol,2001,2(4):667-673.
  • 3Parikh AA,Ellis LM.The vascular endothelial growth factor family and its receptor[J].Hematol Oncol Clin North Am,2004,18(5):951-957.
  • 4Kabbinavar F,Hurwitz HI,Fehrenbacher L,et al.Phase Ⅱ,randomized trial comparing bevacizumab plus fluorouracil(FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer[J].J Clin Oncol,2003,21(1):60-65.
  • 5Kuenen BC,Rosen L,Smit EF,et al.Dose-finding and Pharmascokinetic study of cisplatin,gemcitabine,and SU5416 in patients with solid tumors[J].J Clin Oncol,2002,20(4):1657-1667.
  • 6Bobek V,Kovarik J.Antitumor and antimetastatic effect of warfarin and heparins[J].Biomed Pharmacother,2004,58(2):213-219.
  • 7Weidner N,Folkman J,Pozza F,et al.Tumor angiogenesis:a new significance and independent prognostic indicator in early-stage breast carcinoma[J].J Natl Cancer Inst,1992,84(7):1875-1886.
  • 8Jansen B,Zangemeister Wittke U.Antisense therapy for cancer-the time of truth[J].Lancet Oncol,2002,3(11):672-683.
  • 9Forster y,Meye A,Krause S,et al.Antisense-mediated VEGF suppression in bladder and breast cancer cells[J].Cancer Lett,2004,212(1):95-103.
  • 10Takahashi H,Ebihara S,Okazaki T,et al.A comparison of the effects of unfractionated heparin,dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity[J].Br J Pharmacol,2005,146(3):333-343.

引证文献1

肿瘤防治研究
2005年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部